학술논문
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
Document Type
article
Author
Margherita Zen; Mariele Gatto; Roberto Depascale; Francesca Regola; Micaela Fredi; Laura Andreoli; Franco Franceschini; Maria Letizia Urban; Giacomo Emmi; Fulvia Ceccarelli; Fabrizio Conti; Alessandra Bortoluzzi; Marcello Govoni; Chiara Tani; Marta Mosca; Tania Ubiali; Maria Gerosa; Enrica P. Bozzolo; Valentina Canti; Paolo Cardinaletti; Armando Gabrielli; Giacomo Tanti; Elisa Gremese; Ginevra De Marchi; Salvatore De Vita; Serena Fasano; Francesco Ciccia; Giulia Pazzola; Carlo Salvarani; Simone Negrini; Andrea Di Matteo; Rossella De Angelis; Giovanni Orsolini; Maurizio Rossini; Paola Faggioli; Antonella Laria; Matteo Piga; Alberto Cauli; Salvatore Scarpato; Francesca Wanda Rossi; Amato De Paulis; Enrico Brunetta; Angela Ceribelli; Carlo Selmi; Marcella Prete; Vito Racanelli; Angelo Vacca; Elena Bartoloni; Roberto Gerli; Elisabetta Zanatta; Maddalena Larosa; Francesca Saccon; Andrea Doria; Luca Iaccarino
Source
Journal of Personalized Medicine, Vol 13, Iss 4, p 691 (2023)
Subject
Language
English
ISSN
2075-4426
Abstract
Aim. To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods. All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (p = 0.034 and p = 0.028, respectively). Conclusions. Belimumab led to clinical improvement in a significant proportion of patients with joint or skin involvement in a real-life setting and was associated with a glucocorticoid-sparing effect. A significant proportion of patients with a partial response at 6 months achieved remission later on during follow-up.